Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: A population-based prospective study

PLoS Negl Trop Dis. 2023 Jun 28;17(6):e0011178. doi: 10.1371/journal.pntd.0011178. eCollection 2023 Jun.

Abstract

Background: Community-directed treatment with ivermectin (CDTi) is used to eliminate onchocerciasis. However, despite 25 years of annual CDTi in Mahenge, Tanzania, the prevalence of onchocerciasis and onchocerciasis-associated epilepsy remained high in certain rural villages. Therefore, in 2019, bi-annual CDTi was introduced in the area. This study assessed the impact of the programme on the incidence of epilepsy in four villages.

Methodology: Door-to-door epilepsy surveys were conducted prior to (2017/18) and after (2021) implementing a bi-annual CDTi program. All household members were screened for epilepsy symptoms using a validated questionnaire, and suspected cases were examined by a medical doctor to confirm/reject the diagnosis of epilepsy. The prevalence and annual incidence of epilepsy, including nodding syndrome, were calculated with 95% Wilson confidence intervals with continuity correction. The latter was also done for CDTi coverage in 2016 and 2021.

Results: Precisely 5,444 and 6,598 persons were screened for epilepsy before and after implementing the intervention. The CDTi coverage of the overall population was 82.3% (95%CI: 81.3-83.2%) in 2021 and sustained in both distribution rounds (81.5% and 76.8%). The coverage was particularly high in children and teenagers aged 6 to 18 years (93.2%, 95%CI: 92.1-94.2%). The epilepsy prevalence remained similar: 3.3% (95%CI: 2.9-3.9%) in 2017/18 versus 3.1% (95%CI: 2.7-3.5%) in 2021. However, the incidence of epilepsy declined from 177.6 (95%CI: 121.2-258.5) in 2015-2017 and 2016-2018 to 45.5 (95%CI: 22.2-89.7) in 2019-2021 per 100,000 persons-years. The incidence of probable nodding syndrome varied from 18.4 (95%CI: 4.7-58.5) to 5.1 (95%CI: 0.3-32.8). None of the nine incidence cases of epilepsy for which information on ivermectin intake was available took ivermectin in the year they developed their first seizures.

Conclusion: A bi-annual CDTi programme should be implemented in areas with high prevalence of onchocerciasis and epilepsy. High CDTi coverage among children is particularly important to prevent onchocerciasis-associated epilepsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antiparasitic Agents / therapeutic use
  • Child
  • Epilepsy* / drug therapy
  • Epilepsy* / epidemiology
  • Epilepsy* / etiology
  • Humans
  • Incidence
  • Ivermectin / therapeutic use
  • Nodding Syndrome* / epidemiology
  • Onchocerciasis* / complications
  • Onchocerciasis* / drug therapy
  • Onchocerciasis* / epidemiology
  • Prevalence
  • Prospective Studies
  • Tanzania / epidemiology

Substances

  • Ivermectin
  • Antiparasitic Agents

Grants and funding

The study was funded by Flemish University development cooperation (VLIR-UOS) (671055 to RC), Research Foundation Flanders (FWO) (G0A0522N to RC), and La Caixa Foundation (B005782 to L-JA). The funders had no role in the design, execution, interpretation, or writing of the study.